NRx Defense Systems wins initial $11.18 million DARPA prime contract for SPARC — TMS depression trial
NRx Defense Systems, a NRX Pharmaceuticals unit, won a DARPA prime contract worth USD 11.18 million for resistant depression research. Funding supports the SPARC-TMS study, testing single-day robotic neuronavigated TMS combined with investigational drug NRX-101. Trial slated to enroll at McLean Hospital, Arizona State